Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/24200
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18076/20274 (89%)
Visitors : 4867248      Online Users : 1595
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/24200


    Title: Design and Evaluate Anticancer Potential of if Haloacetamidines- Dderived PAD4 Inhibitors
    Authors: Yuji Wang (王玉記)
    Pingxin Li
    Shu Wang
    Jing Hu
    Megan Fisher
    Kira Oshaben
    Na Zhao
    Gong Chen
    Yanming Wang
    Date: 2011
    Issue Date: 2011-06-23 14:56:56 (UTC+8)
    Abstract: Histones play an important role in human cells by organizing DNA to form basic structural units of chromatin termed nucleosomes. One emerging strategies for cancer treatment is to target enzymes that covalently modify histones thereby regulating cell proliferation and death. For example, histone deacetylase (HDAC) inhibitor, SAHA (also called voriostat or Zolina), has been used successfully in clinical trials and approved by FDA as a monotherapy compound or in comibination with various anticancer drugs. We anticipate that our research will offer the chemical and biological groundworJc to develop a PAD4 inhibitor for cancer treatment in combination with other anticticancer drugs, especially with the HDAC inhibitor SAHA. So the lead compounds, Cl-amidine derivatives were synthesized using a newly designed solution-based method to improve the specificity and bioavailability of the inhibitors. We tested the anticancer activity of the PAD4 inhibitor Cl-amidine and its derivatives and their anticancer activity in combination with the HDAC inhibitor SAHA. Taken together, we identify PAD4 as a promising drug target for cancer treatment, suggesting that epigenetic mechanisms can be explored to develop novel strategies for cancer chemotherapy.
    Relation: 2011年台俄有機、藥物與生物化學交流暨藥物化學研討會,起迄日:2011/04/06~2011/04/05,地點:溪頭台大實驗林
    Appears in Collections:[Pharmacy and Science] 2011 Taiwanese-Russian Organic, Medicinal and Bio Chemistry Interactions & PST Medicinal Chemistry Symposium

    Files in This Item:

    File Description SizeFormat
    op-12.pdf90KbAdobe PDF655View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback